Total Payments
$1.1M
2024 Payments
$129,350
Companies
46
Transactions
2,176
Medicare Patients
201
Medicare Billing
$30,514
Payment Breakdown by Category
Other$795,232 (74.3%)
Travel$163,484 (15.3%)
Consulting$66,533 (6.2%)
Food & Beverage$45,428 (4.2%)
Gifts$39.10 (0.0%)
Education$7.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $616,827 | 264 | 57.6% |
| Honoraria | $178,405 | 77 | 16.7% |
| Travel and Lodging | $163,484 | 491 | 15.3% |
| Consulting Fee | $66,533 | 18 | 6.2% |
| Food and Beverage | $45,428 | 1,322 | 4.2% |
| Gift | $39.10 | 2 | 0.0% |
| Education | $7.09 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $207,021 | 311 | $0 (2024) |
| Tris Pharma Inc | $197,243 | 340 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $168,461 | 227 | $0 (2024) |
| Corium, LLC | $159,071 | 178 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $111,778 | 171 | $0 (2022) |
| Neos Therapeutics, LP | $50,878 | 121 | $0 (2023) |
| Shire North American Group Inc | $43,966 | 92 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $40,285 | 86 | $0 (2024) |
| Adlon Therapeutics L.P. | $24,249 | 24 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23,172 | 79 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $129,350 | 238 | Supernus Pharmaceuticals, Inc. ($53,075) |
| 2023 | $171,732 | 276 | Corium, LLC ($76,858) |
| 2022 | $113,082 | 253 | Corium, LLC ($40,610) |
| 2021 | $82,633 | 258 | Supernus Pharmaceuticals, Inc. ($33,394) |
| 2020 | $21,065 | 149 | Teva Pharmaceuticals USA, Inc. ($5,153) |
| 2019 | $161,931 | 298 | Tris Pharma Inc ($61,243) |
| 2018 | $199,683 | 357 | Sunovion Pharmaceuticals Inc. ($75,216) |
| 2017 | $191,247 | 347 | Tris Pharma Inc ($45,696) |
All Payment Transactions
2,176 individual payment records from CMS Open Payments — Page 3 of 88
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/20/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: ADHD | ||||||
| 08/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Neuropsychiatry | ||||||
| 08/15/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $30.85 | General |
| Category: PSYCHIATRY | ||||||
| 08/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.23 | General |
| Category: Neuropsychiatry | ||||||
| 08/13/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $35.29 | General |
| Category: Neuroscience | ||||||
| 08/13/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 08/09/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $965.25 | General |
| Category: PSYCHIATRY | ||||||
| 08/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: SCHIZOPHRENIA | ||||||
| 08/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: PSYCHIATRY | ||||||
| 08/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $2.05 | General |
| Category: PSYCHIATRY | ||||||
| 07/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,808.00 | General |
| Category: PSYCHIATRY | ||||||
| 07/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,808.00 | General |
| Category: PSYCHIATRY | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $88.15 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $88.14 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $32.82 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $31.20 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $8.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $8.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/30/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,750.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/30/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/30/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 07/30/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $770.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 49 | 133 | $16,695 | $7,840 |
| 2022 | 2 | 53 | 143 | $18,105 | $8,427 |
| 2021 | 2 | 49 | 104 | $14,420 | $6,480 |
| 2020 | 2 | 50 | 128 | $17,820 | $7,767 |
Total Patients
201
Total Services
508
Medicare Billing
$30,514
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 77 | $11,935 | $5,378 | 45.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 23 | 56 | $4,760 | $2,462 | 51.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 86 | $13,330 | $5,864 | 44.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 24 | 57 | $4,775 | $2,563 | 53.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 75 | $12,245 | $5,100 | 41.7% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 18 | 29 | $2,175 | $1,379 | 63.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 31 | 95 | $15,345 | $6,051 | 39.4% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 19 | 33 | $2,475 | $1,716 | 69.3% |
About Dr. Alice Mao, MD
Dr. Alice Mao, MD is a Child & Adolescent Psychiatry healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851309488.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alice Mao, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $129,350 received in 2024. These payments were reported across 2,176 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($616,827).
As a Medicare-enrolled provider, Mao has provided services to 201 Medicare beneficiaries, totaling 508 services with total Medicare billing of $30,514. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Houston, TX
- Active Since 08/03/2006
- Last Updated 06/06/2013
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1851309488
Products in Payments
- REXULTI (Drug) $206,832
- Dyanavel XR (Drug) $167,063
- Azstarys (Drug) $109,240
- LATUDA (Drug) $107,696
- QELBREE (Drug) $70,967
- Qelbree (Drug) $53,038
- Adzenys XR-ODT (Drug) $50,838
- AZSTARYS (Drug) $49,832
- AUSTEDO (Drug) $39,116
- MYDAYIS (Drug) $37,791
- Trintellix (Drug) $31,398
- ADHANSIA XR (Drug) $24,249
- Quillichew ER (Drug) $21,992
- VRAYLAR (Drug) $11,307
- Quillivant (Drug) $6,867
- JORNAY PM (Drug) $5,196
- SPRAVATO (Drug) $3,578
- Aptensio XR (Drug) $3,327
- Auvelity (Drug) $2,179
- ZolpiMist (Drug) $1,883
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Houston
Matthew Brams, M.d, M.D
Child & Adolescent Psychiatry — Payments: $2.0M
Child & Adolescent Psychiatry $2.0M
Dr. Peter Ly, M.d, M.D
Child & Adolescent Psychiatry — Payments: $13,221
Child & Adolescent Psychiatry $13,221
Dr. Jay Tarnow, Md, MD
Child & Adolescent Psychiatry — Payments: $6,230
Child & Adolescent Psychiatry $6,230
Dr. Ann Marie Menendez-Caldwell, M.d, M.D
Child & Adolescent Psychiatry — Payments: $5,661
Child & Adolescent Psychiatry $5,661
Dr. Monica Grover, Md, MD
Child & Adolescent Psychiatry — Payments: $5,573
Child & Adolescent Psychiatry $5,573
Kay Lewis, M.d, M.D
Child & Adolescent Psychiatry — Payments: $4,622
Child & Adolescent Psychiatry $4,622